Novo-Nordisk A/S
NVO Real Time Price USD$NVO is featured in our Tom Carper strategy.
All StrategiesRecent trades of NVO by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NVO holdings by institutional investors
Quarterly net insider trading by NVO's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$1,730,000 Oct 20, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$1,050,000 Jul 16, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$2,330,000 Apr 18, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
-
$1,240,000 Jan 17, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
-
$780,000 Oct 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,060,000 Jul 19, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$50,000 Apr 23, 2024 Issue: Health Issues Budget/Appropriations
-
$50,000 Apr 22, 2024 Issue: Health Issues
-
$60,000 Apr 22, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Apr 22, 2024 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
-
$1,490,000 Apr 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$60,000 Feb 07, 2024 Issue: Budget/Appropriations Pharmacy Medicare/Medicaid Health Issues
-
$600,000 Oct 19, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
NVO Estimated quarterly lobbying spending
NVO Revenue by Segment or Geography
New NVO patent grants
-
Patent Title: Two-part hinged needle magazine Apr. 28, 2015
-
Patent Title: Acylated exendin-4 compounds Apr. 21, 2015
-
Patent Title: Determination of position of injection needle Apr. 14, 2015
-
Patent Title: Double-acylated glp-1 derivatives with a linker Apr. 14, 2015
-
Patent Title: Antibody toxin conjugates Apr. 14, 2015
-
Patent Title: Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) Apr. 07, 2015
-
Patent Title: Absolute position determination of movably mounted member in medication delivery device Mar. 31, 2015
-
Patent Title: Device for injecting apportioned doses of liquid drug Mar. 31, 2015
-
Patent Title: Protease stabilized, pegylated insulin analogues and uses thereof Mar. 24, 2015
-
Patent Title: Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof Mar. 17, 2015
-
Patent Title: Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography Mar. 03, 2015
-
Patent Title: Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids Feb. 24, 2015
-
Patent Title: Pharmaceutical compositions comprising glp-1 peptides or extendin-4 and a basal insulin peptide Jan. 20, 2015
-
Patent Title: Insulin derivative Jan. 13, 2015
-
Patent Title: Purification of proteins using preparative reverse phase chromatography (rpc) Dec. 30, 2014
-
Patent Title: Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Dec. 30, 2014
-
Patent Title: Seal for a prefilled medical jet injection device Dec. 30, 2014
-
Patent Title: Glycopegylated erythropoietin Dec. 23, 2014
-
Patent Title: Medical injection device with large, mechanical cipher dose display Dec. 23, 2014
-
Patent Title: One pot desialylation and glycopegylation of therapeutic peptides Dec. 16, 2014
-
Patent Title: Injection device Dec. 16, 2014
-
Patent Title: Anti-nkg2a antibodies and uses thereof Dec. 02, 2014
-
Patent Title: Gearing mechanism for an injection device Dec. 02, 2014
-
Patent Title: Glucagon-like peptide-1 derivatives and their pharmaceutical use Nov. 25, 2014
-
Patent Title: Amylin derivatives Nov. 25, 2014
-
Patent Title: Medical injection device with time delay indicator Nov. 25, 2014
-
Patent Title: Human insulin containing additional disulfide bonds Nov. 11, 2014
-
Patent Title: Single-chain insulin Nov. 11, 2014
-
Patent Title: Pharmaceutical solution of non covalently bound albumin and acylated insulin Oct. 21, 2014
-
Patent Title: Selective modification of proteins Oct. 14, 2014
-
Patent Title: Insulin derivatives Oct. 14, 2014
-
Patent Title: Cap lock Oct. 14, 2014
-
Patent Title: Glycopegylation methods and proteins/peptides produced by the methods Oct. 07, 2014
-
Patent Title: Methods of treating steroid-induced obesity using glp-1 agonists Oct. 07, 2014
-
Patent Title: Insulin derivatives containing additional disulfide bonds Oct. 07, 2014
-
Patent Title: Stable formulation of modified glp-1 Sep. 30, 2014
-
Patent Title: Anti-c5a receptor antibodies Sep. 30, 2014
-
Patent Title: Nucleotide sugar purification using membranes Sep. 23, 2014
-
Patent Title: Growth hormones with prolonged in-vivo efficacy Sep. 23, 2014
-
Patent Title: Derivatives of cgrp Sep. 16, 2014
-
Patent Title: Method for making acylated polypeptides Sep. 16, 2014
-
Patent Title: Insulin derivatives Sep. 09, 2014
-
Patent Title: Methods of refolding mammalian glycosyltransferases Sep. 02, 2014
-
Patent Title: Reservoir device with integrated mounting means Sep. 02, 2014
-
Patent Title: Glp-1 analogues and derivatives Aug. 26, 2014
-
Patent Title: Insulin analogues containing additional disulfide bonds Aug. 26, 2014
-
Patent Title: Method for making polypeptides Aug. 26, 2014
-
Patent Title: Humanized anti-human nkg2a monoclonal antibody Aug. 05, 2014
-
Patent Title: Insulin derivative Aug. 05, 2014
-
Patent Title: Method of acylating a peptide or protein Jul. 29, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NVO from public contracts
Recent insights relating to NVO
Recent picks made for NVO stock on CNBC
ETFs with the largest estimated holdings in NVO
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NVO stock a Buy, Sell, or Hold?
- What is the price target for $NVO stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NVO stock?
- Who owns the most shares of $NVO stock?
- What funds own $NVO stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.